Kodiak Sciences announced positive topline results from the Phase 3 GLOW2 study on March 26, 2026, showing Zenkuda (tarcocimab tedromer) superior to sham in diabetic retinopathy.1
62.5% of Zenkuda-treated patients achieved ≥2-step improvement in DRSS vs. 3.3% sham (p<0.0001).13
85% risk reduction in sight-threatening complications (2.4% Zenkuda vs. 15.8% sham, p=0.0001).1
Favorable safety:
0% intraocular inflammation, 2.3% cataract rate (vs. 1.6% sham).1
Builds on GLOW1 success; DAYBREAK Phase 3 topline expected Q3 2026.1
No search results provided information on Innate discontinuing an anti-CD20 program.
Sources:
1. https://www.prnewswire.com/news-releases/kodiak-sciences-announces-positive-topline-results-in-glow2-the-second-phase-3-study-in-diabetic-retinopathy-demonstrating-superiority-of-zenkuda-tarcocimab-tedromer-over-sham-302725841.html
3. https://trial.medpath.com/news/93f5cb40983ac922/kodiak-sciences-zenkuda-achieves-primary-endpoint-in-phase-3-diabetic-retinopathy-trial